OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

In newly diagnosed GBM,

Optune was safely combined with TMZ

No significant increase in serious AEs compared with TMZ alone1,2

AE Chart AE Chart

No significant increase in serious AEs compared with TMZ alone1

  • The most common (≥10%) AEs involving Optune in combination with TMZ were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression3
  • A slightly higher incidence of grade 1/2 AEs was seen in some of the systems in the Optune + TMZ arm of the study. This is most likely a reflection of the longer duration of TMZ treatment due to the increase in PFS seen in the treatment group1
  • The rate of grade 1/2 medical device site reaction was 52% for Optune + TMZ compared with 0% for TMZ alone, and severe (grade 3) skin involvement occurred in 2% of patients treated with Optune + TMZ1,2
  • Grade 3/4 AEs were well balanced between arms. None of the systemic grade 3/4 AEs were considered related to Optune by any of the investigators1
  • Mild-to-moderate skin irritation, the most common device-related side effect with Optune, was easily manageable, reversible, and did not result in treatment discontinuation1,2

AEs, adverse events; GBM, glioblastoma; TMZ, temozolomide.

References: 1. Optune. Instructions for Use for Glioblastoma Multiforme. Novocure; 2019. 2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 3. Novocure Data on File OPT-103.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).